SCH-530348

Known as: SCH 530348, SCH530348 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2017
024620082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Neutrophils are key effector cells of the innate immune response to pathogenic bacteria, but excessive neutrophilic inflammation… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
BACKGROUND Community-acquired pneumonia is commonly caused by Streptococcus pneumoniae, which is associated with excessive… (More)
Is this relevant?
2015
2015
To evaluate the question of whether protease activated receptor-1 (PAR-1) antagonist is a potential therapeutic target in… (More)
Is this relevant?
2013
2013
This randomized, open-label, parallel group study examined the effects of food, antacid, and age on the pharmacokinetics of… (More)
Is this relevant?
Review
2012
Review
2012
Currently available antiplatelet agents have shown improved short- and long-term clinical outcomes but are associated with… (More)
Is this relevant?
2011
2011
Vorapaxar (SCH 530348), a potent oral thrombin protease-activated receptor 1 antagonist, is being developed as an antiplatelet… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2011
2011
SCH 530348 is a safe and effective oral anti-platelet agent for patients with acute coronary syndrome. Clinical study results… (More)
Is this relevant?
2010
2010
AIM A previous phase 2 study of patients undergoing non-urgent PCI treated with SCH530348 plus aspirin and clopidogrel tended to… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND An antithrombotic drug is needed that safely reduces cardiovascular events in patients undergoing percutaneous… (More)
Is this relevant?
Review
2009
Review
2009
SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of… (More)
Is this relevant?